Novo Nordisk (NVO) has been downgraded to sell by analysts as its stock continues to suffer one of the steepest declines seen among major pharmaceutical companies in recent years.
The Danish drugmaker’s market capitalization has fallen nearly 69% since hitting an all-time high of $635.7 billion in June 2024, wiping out hundreds of billions in shareholder value.
Danish shares had fallen roughly 5% year-to-date coming into recent trading, even as the company generated some optimism around its newly launched Wegovy pill.
Analysts have grown increasingly concerned that Novo Nordisk is less diversified than its current and future competitors, leaving it dangerously exposed to the U.S. market.
Drug pricing pressure in the United States has intensified significantly, with Novo Nordisk confirming it will cut the list price of Ozempic and Wegovy to $675 a month beginning January 2027.
That pricing concession has rattled investors who once viewed the GLP-1 franchise as an almost untouchable revenue engine capable of sustaining growth for years to come.
Jefferies analysts delivered another sharp blow when they reported that Novo Nordisk’s drug ziltivekimab “did not achieve” goals to reduce major adverse cardiovascular events in a late-stage clinical trial.
Jefferies wrote that the ziltivekimab failure effectively erased a growth opportunity worth more than $10 billion annually beyond Ozempic and Wegovy, a significant loss for the company’s pipeline ambitions.
Bank of America also downgraded the stock, a move that came just one day after Novo Nordisk slashed its full-year outlook and announced a new CEO, sending shares plummeting nearly 22% in a single session.
Berenberg downgraded the stock to “Hold,” arguing that excitement around the oral version of Wegovy, once considered a central growth driver, is already priced into the current valuation.
Quarterly results and guidance have done little to resolve Wall Street’s biggest concern, namely whether Novo Nordisk has a convincing path back to sustainable growth as competition from Eli Lilly (LLY) intensifies.
Despite being first to market with a GLP-1 drug for weight loss, Novo Nordisk now captures only about 40% of the market, while rival Eli Lilly (LLY) commands approximately 60%, according to most estimates.
The competitive gap between the two companies has widened considerably, and analysts see little near-term catalyst that would allow Novo Nordisk to reclaim its dominant position in the GLP-1 space.
